Combined Ultrasound Hepatic and Renal Denervation for Essential Hypertension (uHRDN)
Safety, Efficacy, and Clinical Feasibility of an Ultrasound Denervation System in Subjects With Essential Hypertension: A Prospective, Multicenter, Open-Label, Single-Arm, Exploratory Study
This study will evaluate the safety and feasibility of a procedure that uses ultrasound energy to treat nerves around the arteries that supply the kidneys and liver. It will also assess whether blood pressure changes after the procedure in people whose high blood pressure remains inadequately controlled despite medication.
All participants who qualify will receive the study procedure. The study team will check for major safety events during the procedure and through 30 days afterward. The team will also compare the average systolic blood pressure measured over 24 hours before the procedure and at the 6-month follow-up.
The study will also look at changes in blood pressure medications and, for participants with type 2 diabetes, changes in blood sugar control.
研究概览
详细说明
This is a prospective, multicenter, open-label, single-arm exploratory study with a planned enrollment of 10 participants. The study includes participants with essential hypertension that remains inadequately controlled after at least 4 weeks of fixed-dose combination antihypertensive therapy. Participants may have hypertension with or without type 2 diabetes.
Before the procedure, computed tomography angiography or magnetic resonance angiography is used to assess vascular anatomy. Digital subtraction angiography is used during the procedure to confirm anatomical suitability. The investigational system consists of a single-use ultrasound ablation catheter and an ultrasound ablation generator. Treatment targets the main renal arteries and the main trunk of the common hepatic artery. First-order renal artery branches may also be treated if their anatomy meets the device requirements.
The study will summarize safety, blood pressure changes, and procedural feasibility descriptively. Measures of glucose metabolism will be explored in participants with type 2 diabetes.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:JinXin Tian
- 电话号码:8618817939689
- 邮箱:sunny.tian@han-med.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Age 18 to 75 years, inclusive.
-
Diagnosed with essential hypertension and inadequately controlled blood pressure, with or without type 2 diabetes mellitus (T2DM).
-
After providing informed consent and after the investigator confirms that switching therapy is safe, participants must take study-supplied amlodipine 5 mg/day and irbesartan 150 mg/day. After at least 28 days of standardized therapy, office systolic blood pressure must be at least 150 mmHg and less than 180 mmHg, and mean 24-hour ambulatory systolic blood pressure must be at least 135 mmHg and less than 170 mmHg, as confirmed by ambulatory blood pressure monitoring.
-
Participants with T2DM must meet all of the following:
- Body mass index of at least 24 kg/m².
- HbA1c of 7.0% to 9.0% at screening or within the preceding 3 months, and again on preprocedural retesting at Visit 3.
- No changes in the types or doses of glucose-lowering medications for at least 4 weeks before Visit 3. In principle, the regimen should remain stable until completion of the 6-month primary endpoint assessment.
Exclusion Criteria:
-
Anatomy of either main renal artery or the main trunk of the common hepatic artery unsuitable for study treatment. Unsuitability of first-order renal artery branches for additional treatment is permitted.
-
Any of the following on preprocedural computed tomography angiography, magnetic resonance angiography, or renal angiography:
- Greater than 50% diameter stenosis in either main renal artery or the common hepatic artery.
- Diameter less than 3 mm or greater than 8 mm in either main renal artery or the common hepatic artery.
-
Previous renal artery denervation or hepatic artery denervation.
-
History of New York Heart Association (NYHA) class III or IV heart failure within 6 months before screening.
-
Stroke or transient ischemic attack within 6 months before screening, or any prior stroke resulting in permanent disability.
-
Type 1 diabetes mellitus, or insulin use within 6 months before screening in participants with T2DM.
-
Secondary hypertension.
-
Estimated glomerular filtration rate below 40 mL/min/1.73 m², calculated using the 2021 CKD-EPI creatinine equation.
-
Pregnancy, breastfeeding, or planned pregnancy during the study.
-
Severe concomitant respiratory disease requiring long-term oxygen therapy or mechanical ventilation.
-
History or evidence of active or suspected chronic liver or biliary tract disease.
-
Current or previous chronic pancreatitis.
-
Active severe infection, a marked bleeding tendency, or inability to receive perioperative anticoagulant or antiplatelet therapy.
-
Any other condition that, in the investigator's judgment, precludes participation in the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Combined Ultrasound Hepatic and Renal Denervation
All enrolled participants receive combined ultrasound hepatic and renal denervation using the investigational ultrasound denervation system. |
The investigational system consists of a single-use ultrasound ablation catheter (model HR35-1050) and an ultrasound ablation generator (model U10-HR). The system delivers ultrasound energy for denervation along the main renal arteries and the main trunk of the common hepatic artery. First-order renal artery branches may also be treated if their anatomy meets the device requirements. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Mean 24-Hour Ambulatory Systolic Blood Pressure
大体时间:Baseline (Visit 2) and 6 months after the procedure
|
Change in mean 24-hour systolic blood pressure, measured by ambulatory blood pressure monitoring and reported in mmHg. Change is calculated as the 6-month value minus the baseline (Visit 2) value. |
Baseline (Visit 2) and 6 months after the procedure
|
|
Incidence of the composite endpoint of major safety events within 30 days after the procedure.
大体时间:From vascular puncture at the start of the procedure through postprocedure Day 30, inclusive
|
Percentage of participants with at least one prespecified event: all-cause death, access-site complications requiring transfusion or invasive intervention or causing or prolonging hospitalization, target artery complications requiring intervention, new myocardial infarction, stroke, transient ischemic attack or other fatal, life-threatening or hospitalization-requiring cardiovascular or cerebrovascular events, acute kidney injury requiring dialysis or other serious renal events causing or prolonging hospitalization, acute liver failure or serious liver injury causing or prolonging hospitalization, acute pancreatitis, biliary tract or gallbladder complications requiring hospitalization or intervention, or other serious adverse events related to the device or procedure. Event relatedness to the device and to the procedure is assessed separately. |
From vascular puncture at the start of the procedure through postprocedure Day 30, inclusive
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Office Systolic Blood Pressure
大体时间:Baseline (Visit 2) and 6 months after the procedure
|
Change in office systolic blood pressure, reported in mmHg, calculated as the 6-month value minus the baseline (Visit 2) value. |
Baseline (Visit 2) and 6 months after the procedure
|
|
Change From Baseline in Office Diastolic Blood Pressure
大体时间:Baseline (Visit 2) and 6 months after the procedure
|
Change in office diastolic blood pressure, reported in mmHg, calculated as the 6-month value minus the Visit 2 value. |
Baseline (Visit 2) and 6 months after the procedure
|
|
Change From Baseline in Mean 24-Hour Ambulatory Diastolic Blood Pressure
大体时间:Baseline (Visit 2) and 6 months after the procedure
|
Change in mean 24-hour diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM), reported in mmHg. |
Baseline (Visit 2) and 6 months after the procedure
|
|
Change From Baseline in Mean Daytime Ambulatory Systolic Blood Pressure
大体时间:Baseline (Visit 2) and 6 months after the procedure
|
Change in mean daytime systolic blood pressure measured by ABPM, reported in mmHg. |
Baseline (Visit 2) and 6 months after the procedure
|
|
Change From Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure
大体时间:Baseline (Visit 2) and 6 months after the procedure
|
Change in mean daytime diastolic blood pressure measured by ABPM, reported in mmHg. |
Baseline (Visit 2) and 6 months after the procedure
|
|
Change From Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure
大体时间:Baseline (Visit 2) and 6 months after the procedure
|
Change in mean nighttime systolic blood pressure measured by ABPM, reported in mmHg. |
Baseline (Visit 2) and 6 months after the procedure
|
|
Change From Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure
大体时间:Baseline (Visit 2) and 6 months after the procedure
|
Change in mean nighttime diastolic blood pressure measured by ABPM, reported in mmHg. |
Baseline (Visit 2) and 6 months after the procedure
|
|
Proportion of Participants With Controlled Office Systolic Blood Pressure
大体时间:6 months after the procedure
|
Percentage of participants with office systolic blood pressure below 140 mmHg at 6 months. |
6 months after the procedure
|
|
Change From Baseline in the Composite Antihypertensive Medication Index
大体时间:Baseline (Visit 2) and 6 months after the procedure
|
Change in the protocol-defined composite antihypertensive medication index from Visit 2 to 6 months. |
Baseline (Visit 2) and 6 months after the procedure
|
|
Change From Baseline in Glycated Hemoglobin in Participants With Type 2 Diabetes
大体时间:Baseline (Visit 3) and 6 months after the procedure
|
Change in glycated hemoglobin (HbA1c), reported in percentage points, in participants with concomitant type 2 diabetes. |
Baseline (Visit 3) and 6 months after the procedure
|
|
Change From Baseline in Fasting Plasma Glucose in Participants With Type 2 Diabetes
大体时间:Baseline (Visit 3) and 6 months after the procedure
|
Change in fasting plasma glucose in participants with concomitant type 2 diabetes. |
Baseline (Visit 3) and 6 months after the procedure
|
|
Changes in Glucose-Lowering Medication Use in Participants With Type 2 Diabetes
大体时间:Baseline (Visit 3) and 6 months after the procedure
|
Changes in the types and doses of glucose-lowering medications in participants with concomitant type 2 diabetes. |
Baseline (Visit 3) and 6 months after the procedure
|
|
Device Success Rate
大体时间:During the procedure through device withdrawal
|
Percentage of participants with successful device delivery, completion of planned energy delivery, and safe device withdrawal, without a device malfunction that prevents treatment completion. |
During the procedure through device withdrawal
|
|
Procedural Success Rate
大体时间:During the procedure through procedure completion
|
Percentage of participants in whom the intended ablation is completed at anatomically appropriate sites, including at least two sites in total across both kidneys and at least one site in the common hepatic artery, with the intended procedural objective achieved and no serious intraprocedural complications. |
During the procedure through procedure completion
|
|
Incidence of New Target Artery Stenosis or Vascular Lesions Requiring Intervention
大体时间:6 months after the procedure
|
Percentage of participants with new diameter stenosis greater than 70% in a main renal artery, a treated first-order renal artery branch, or the main trunk of the common hepatic artery, or with a relevant vascular lesion requiring intervention. Assessed by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography if needed. |
6 months after the procedure
|
|
Proportion of Participants With at Least a 30% Decline in Estimated Glomerular Filtration Rate
大体时间:Baseline and 6 months after the procedure, with repeat testing within 7 days of a qualifying result
|
Percentage of participants with a decline of at least 30% in estimated glomerular filtration rate from baseline. The first qualifying result is confirmed by repeat testing within 7 days, after excluding clearly reversible causes. |
Baseline and 6 months after the procedure, with repeat testing within 7 days of a qualifying result
|
|
Changes From Baseline in Hepatobiliary Laboratory Parameters
大体时间:Baseline (Visit 3) and 6 months after the procedure
|
Changes in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, and direct bilirubin. |
Baseline (Visit 3) and 6 months after the procedure
|
|
Incidence of Hepatobiliary Complications
大体时间:Assessed at 6 months after the procedure
|
Incidence of acute liver injury, biliary stricture or obstruction, acute cholecystitis, and other hepatobiliary complications requiring hospitalization or clinical intervention. |
Assessed at 6 months after the procedure
|
|
Changes From Baseline in Amylase and Lipase
大体时间:Baseline and 6 months after the procedure
|
Changes in amylase and lipase from baseline to 6 months. |
Baseline and 6 months after the procedure
|
|
Incidence of Adverse Events Through 6 Months
大体时间:From the start of the procedure through 6 months
|
Percentage of participants with at least one adverse event. |
From the start of the procedure through 6 months
|
|
Incidence of Serious Adverse Events Through 6 Months
大体时间:From the start of the procedure through 6 months
|
Percentage of participants with at least one serious adverse event. |
From the start of the procedure through 6 months
|
合作者和调查者
调查人员
- 首席研究员:Junbo Ge、hongshan Hospital, Fudan University
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- HT-CT-2601-FIM
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The sponsor does not plan to share individual participant data (IPD) from this study with other researchers.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.